• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Bryn Pharma raises $11 million for continued development of its epinephrine nasal spray

Bryn Pharma said that it has raised $11 million in an extension of the financing that raised over $17 million in October 2019 to fund activities related to its BRYN-NDS1C epinephrine nasal spray candidate, which is delivered via Aptar Pharma’s Bidose nasal device. According to Bryn, proceeds from this financing will be used for continued development of BRYN-NDS1C, as well as for regulatory and pre-commercialization activities.

Earlier this year, the company reported data from a Phase 1 PK/PD study of BRYN-NDS1C that compared the nasal spray to Mylan’s EpiPen. The company has said that it plans to submit a 505(b)(2) NDA for the nasal spray.

Bryn Pharma CEO David Dworaczyk commented, “This financing provides us further resources to continue building the value of Bryn Pharma and to bring our disruptive nasal epinephrine product to the large number of patients requiring protection from anaphylactic events. We are pleased with the enthusiastic response to this offering and to the continued support of investors as we forge ahead with this important initiative for anaphylactic patients.”

Read the Bryn Pharma press release.

Share

published on August 4, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews